الفهرس 
Early pregnancy loss (miscarriage)Only 14 pages are availabe for public view
 |  | from | 190 |  |  |
| | | from | 190 | | |
Abstract
Extensive evidence is present regarding the benefit of uterine artery Doppler ultrasound for assessing uteroplacental perfusion and predicting the future development of pre‐eclampsia, fetal growth restriction, placental abruption, and stillbirth in the second trimester. However, the researchers have not so far reached a concrete consensus about using uterine Doppler measurements for predicting the adverse outcomes in the early stages of pregnancy between 6-14 weeks. Progesterone is essential to achieve and maintain a healthy pregnancy. The fact that progestogens were associated with a lower rate of recurrent miscarriage needs to be correlated also with costeffectiveness consideration. The concern regarding the efficacy of oral dydrogesterone compared to vaginal micronized progesterone is addressed. The aim of this work was to evaluate differences in uteroplacental blood flow and pregnancy outcome in women with IRSM following administration of micronized vaginal progesterone versus oral dydrogesteron. This study comprised 90 pregnant women during the period of research from November 2018 to November 2019 at obstetrics clinic of Tanta University hospital clinics. All women had a singleton pregnancy with active cardiac pulsation. 60 patients had history of IRSM within the first trimester, and the patients were divided into 30 pregnant women who received 10 mg of oral dydrogesterone (Duphaston; Abbott Company) twice daily and 30 pregnant women who received 200 mg micronized vaginal progesterone (Prontogest) twice-daily. Moreover, this study recruited 30 pregnant women without history of recurrent miscarriage served as controls and they received folic acid as placebo.